Compare VRTX & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SBUX |
|---|---|---|
| Founded | 1989 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Restaurants |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 122.3B |
| IPO Year | 2007 | 1994 |
| Metric | VRTX | SBUX |
|---|---|---|
| Price | $517.10 | $103.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 36 |
| Target Price | ★ $595.36 | $111.07 |
| AVG Volume (30 Days) | 1.3M | ★ 7.1M |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | ★ 836.54 | 35.58 |
| EPS | ★ 10.90 | 2.21 |
| Revenue | $2,488,652,000.00 | ★ $37,910,600,000.00 |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $10.53 | $3.80 |
| P/E Ratio | $47.77 | ★ $47.09 |
| Revenue Growth | ★ 46.20 | 1.95 |
| 52 Week Low | $412.27 | $81.97 |
| 52 Week High | $568.67 | $111.50 |
| Indicator | VRTX | SBUX |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 47.30 |
| Support Level | $493.75 | $101.95 |
| Resistance Level | $536.58 | $103.69 |
| Average True Range (ATR) | 15.90 | 3.22 |
| MACD | -3.73 | -0.65 |
| Stochastic Oscillator | 4.74 | 7.14 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Starbucks stands out as the world's largest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.